Everything You Need to Know About Graft-vs-host disease for Step 1

Graft-versus-host disease (GVHD) is one of those transplant complications that USMLE loves because it’s conceptually clean once you understand the mechanism: the graft attacks the host. If you can quickly distinguish GVHD from rejection (host attacks graft), you’ll pick up a lot of easy points across immunology, heme/onc, and transplant questions.

---

The 10-Second Definition (Memorize This)

Graft-versus-host disease occurs when immunocompetent donor T cells are transplanted into an immunocompromised recipient, and those donor T cells recognize recipient tissues as foreign and attack them.

Classic setting: Allogeneic hematopoietic stem cell transplant (HSCT) (aka bone marrow transplant)
Also possible: solid organ transplant containing lots of lymphoid tissue (less common)

Not the same as rejection:

• Rejection: host immune system attacks the graft
• GVHD: donor immune system attacks the host

---

High-Yield “When Does GVHD Happen?”

GVHD needs 3 conditions (often tested as a triad):

1. The graft contains immunocompetent T cells (most important)
2. The recipient is immunocompromised (can’t eliminate donor T cells)
3. Recipient expresses antigens not present in the donor (HLA or minor histocompatibility antigens)

HY Association: HLA Matching vs Minor Antigens

Even with perfect HLA matching, GVHD can still occur due to minor histocompatibility antigens, especially H-Y antigens (see below).

---

Pathophysiology (Step-Friendly Mechanism)

Think of GVHD in a few clean steps:

1) Conditioning injury & cytokine priming

Pre-transplant chemo/radiation damages host tissues → releases inflammatory cytokines (e.g., TNF-α, IL-1, IL-6) and activates host APCs.

2) Donor T-cell activation

Donor T cells encounter recipient antigen presentation (HLA differences or minor antigens) → activation and clonal expansion.

3) Effector phase: tissue damage

Activated donor T cells (plus cytokines) attack target organs:

• Skin
• GI tract
• Liver

Mechanisms: cytotoxic T-cell killing + cytokine-mediated injury (e.g., TNF-α contributes to gut damage)

---

Acute vs Chronic GVHD (Know the Pattern)

Acute GVHD

Timing: classically within 100 days of transplant (but can occur later, especially with modern immunosuppression)

Classic triad (very testable):

• Skin: painful maculopapular rash (often starts on palms/soles), can progress to generalized erythroderma and desquamation
• GI: secretory watery diarrhea, abdominal pain, nausea/vomiting
• Liver: cholestatic hepatitis → ↑ bilirubin, ↑ alk phos

Buzz phrase: “rash, jaundice, diarrhea” after allogeneic HSCT

---

Chronic GVHD

Timing: classically after 100 days

Clinical vibe: “autoimmune-like” / “scleroderma-like”

Common features:

• Skin: lichen planus-like changes, sclerodermatous thickening, pigment changes
• Eyes/mouth: sicca syndrome (dry eyes, dry mouth)
• Liver: cholestasis
• Lungs: bronchiolitis obliterans (obstructive symptoms)
• GI: dysphagia (esophageal webs/strictures), malabsorption can occur

High-yield comparison: Chronic GVHD can resemble systemic sclerosis, Sjögren, and other autoimmune diseases.

---

Clinical Presentation: What the USMLE Stem Looks Like

Acute GVHD vignette

• Allogeneic HSCT (often for leukemia)
• 2–8 weeks later: diffuse rash + profuse watery diarrhea + jaundice
• Labs: cholestatic pattern; sometimes pancytopenia is present from transplant context

Chronic GVHD vignette

• Months after HSCT
• Skin tightening, dry eyes/mouth, cholestasis, obstructive lung disease symptoms

---

Diagnosis (What’s Actually Done vs What’s Tested)

USMLE-level diagnosis

Often clinical in the right context. If they give pathology, it’s usually to reinforce organ involvement.

Confirmatory testing (real-world + occasionally tested)

Biopsy of affected organ:

• Skin biopsy: interface dermatitis, apoptotic keratinocytes
• GI biopsy: crypt cell apoptosis, mucosal denudation
• Liver biopsy: bile duct injury, cholestasis

Differential (must distinguish)

• Drug reactions (rash)
• Infection (esp. C. difficile causing diarrhea)
• Hepatic veno-occlusive disease (sinusoidal obstruction syndrome)
• Transplant rejection (relevant mainly for solid organs, not HSCT)

---

Treatment (High Yield for Step 1/2)

Prevention (big concept)

• HLA matching (helps but doesn’t eliminate GVHD)
• Immunosuppression prophylaxis: typically calcineurin inhibitor (tacrolimus or cyclosporine) ± methotrexate/mycophenolate
• T-cell depletion of graft can reduce GVHD risk (tradeoff: higher relapse + infection risk)

Acute GVHD treatment

• High-dose systemic glucocorticoids (first-line)
• Add/optimize immunosuppression (calcineurin inhibitors)
• Steroid-refractory: options include agents that target T-cell signaling/cytokines (institution-dependent)

Chronic GVHD treatment

• Often requires prolonged immunosuppression:
  • Systemic steroids
  • Calcineurin inhibitors and other steroid-sparing agents
• Supportive care: eye lubricants, topical therapies, infection prophylaxis when indicated

---

The H-Y Antigen Association (Super High Yield)

H-Y antigens are minor histocompatibility antigens encoded on the Y chromosome.

Classic high-yield scenario:

• Female donor → male recipient in allogeneic HSCT
• Even if HLA-matched, donor T cells can recognize H-Y peptides as foreign → ↑ risk of GVHD

Why it matters for Step:

• USMLE loves testing that GVHD can occur despite HLA matching because of minor antigens.

---

“Graft-vs-Leukemia” Effect (The Tradeoff You Must Know)

Here’s the twist USMLE wants you to appreciate:

• GVHD is bad (organ damage)
• But donor T cells can also attack residual malignant cells → graft-versus-leukemia (GVL) effect

Clinical implication (testable concept):

• Aggressive T-cell depletion can reduce GVHD but may increase relapse risk due to loss of GVL.

---

Rapid-Fire High-Yield Facts (Exam Checklist)

• GVHD = donor T cells attack recipient
• Most common after allogeneic HSCT
• Target organs: skin, liver, GI
• Acute GVHD: <100 days → rash + diarrhea + jaundice
• Chronic GVHD: >100 days → autoimmune/scleroderma-like + sicca + bronchiolitis obliterans
• H-Y antigen: female donor → male recipient increases risk
• Treatment: steroids + immunosuppressants; prevent with HLA matching and prophylaxis
• GVL effect: donor immunity can help prevent leukemia relapse

---

First Aid Cross-References (Where to Find/Connect It)

Because First Aid editions vary by year, use these as topic-based cross-references (search the term in your copy):

• Immunology → Transplant rejection & GVHD
  • Distinguish hyperacute/acute/chronic rejection vs GVHD
• Heme/Onc → Hematopoietic stem cell transplant complications
  • GVHD + graft-versus-leukemia effect
• Immunology → Hypersensitivity
  • Helpful contrast: GVHD is T-cell mediated (Type IV-like mechanism) but is its own transplant entity
• Micro/ID integration
  • Immunosuppression complications (opportunistic infections) frequently co-tested with GVHD scenarios

Tip: If you see bone marrow transplant + rash/diarrhea/jaundice, don’t overthink it—go straight to GVHD.

---

Quick Table: GVHD vs Rejection (Classic Confusion Point)

---

If you want, I can also generate a one-page “GVHD vs rejection vs veno-occlusive disease” mini-sheet with the most common distinguishing clues and test stems.